Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study

被引：0
|
作者：
Gui, L. [1 ]
Chen, X. [2 ]
He, X. [1 ]
Yang, J. [3 ]
Liu, P. [1 ]
Qin, Y. [1 ]
Shi, Y-K. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, CAMS PUMC, Dept Med Oncol, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360MO
引用
收藏
页码：S1609 / S1610
页数：2
相关论文
共 50 条
  • [21] Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).
    Borel, Christian
    Carinato, Helene
    Pflumio, Carole
    Poprawa, Elodie
    Brahimi, Youssef
    Oriel, Marine
    Vacheret, Clara
    Ravily, Delphine
    Coliat, Pierre
    Petit, Thierry
    Burgy, Mickael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
    Bossi, P.
    Miceli, R.
    Locati, L. D.
    Ferrari, D.
    Vecchio, S.
    Moretti, G.
    Denaro, N.
    Caponigro, F.
    Airoldi, M.
    Moro, C.
    Vaccher, E.
    Sponghini, A.
    Caldara, A.
    Rinaldi, G.
    Ferrau, F.
    Nole, F.
    Lo Vullo, S.
    Tettamanzi, F.
    Hollander, L.
    Licitra, L.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2820 - 2826
  • [23] Platinum/taxane/pembrolizumab vs Platinum/5-fluorouracil/pembrolizumab in recurrent/metastatic Head and Neck Squamous Cell Carcinoma (r/m HNSCC)
    Sun, L.
    Cohen, R.
    Colevas, A. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E34 - E35
  • [24] Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma
    Harrington, K. J.
    William, W. N., Jr.
    Khilnani, A.
    Algazi, A. P.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S683
  • [25] REAL-WORLD TREATMENT PATTERNS AND SURVIVAL WITH FIRST-LINE (1L) PEMBROLIZUMAB plus PLATINUM plus TAXANE THERAPY FOR PATIENTS WITH RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA (R/M HNSCC) IN THE UNITED STATES
    Black, C.
    Hanna, G. J.
    Wang, L.
    Ramakrishnan, K.
    Hair, G.
    Zheng, D.
    Goto, D.
    VALUE IN HEALTH, 2023, 26 (06) : S18 - S18
  • [26] Multicenter Phase 2 Trial of Cis/Carboplatin, nAb-Paclitaxel, and CeTUXimab (CACTUX) as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Adkins, D.
    Ley, J.
    Atiq, O.
    Rigden, C.
    Trinkaus, K.
    Wildes, T. M.
    Oppelt, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1311 - 1312
  • [27] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIAL
    Adkins, Douglas
    Ley, Jessica
    Palka, Kevin
    Jacobs, Miriam
    Liu, Jingxia
    Oppelt, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385
  • [28] Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.
    Fayette, Jerome
    Clatot, Florian
    Brana, Irene
    Saada, Esma
    van Herpen, Carla M. L. -
    Mazard, Thibault
    Perez, Cesar Augusto
    Tabernero, Josep
    Le Tourneau, Christophe
    Hollebecque, Antoine
    Arrula, Virginia Arrazubi
    Fontana, Elisa
    Kato, Shumei
    Sacco, Assuntina G.
    Harandi, Amir
    De Boer, J. P.
    Hellyer, Jessica
    Pennella, Eduardo
    Joe, Andrew K.
    Daste, Amaury
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Pembrolizumab (pembro) plus carboplatin (carbo) plus paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study
    Dzienis, M. R.
    Cundom, J. E.
    Fuentes, C. S.
    Hansen, A. R.
    Nordlinger, M. J.
    Pastor, A. V.
    Oppelt, P.
    Neki, A.
    Gregg, R. W.
    Lima, I. P. F.
    Franke, F. A.
    Da Cunha Junior, G. F.
    Tseng, J. E.
    Loree, T.
    Joshi, A. J.
    Mccarthy, J. S.
    Naicker, N.
    Sidi, Y.
    Gumuscu, B.
    De Castro, G., Jr.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S839 - S840
  • [30] Network meta-analysis (NMA) of pembrolizumab for first-line (1L) treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Ramakrishnan, Karthik
    Mojebi, Ali
    Ayers, Dieter
    Chirovsky, Diana Romana
    Borse, Rebekah
    Keeping, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345